Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T15:37:51.988Z.
Calculation as of: 2026-10-06T15:37:51.988Z.
Quote observation: 2026-10-06T15:35:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$14.04M
EV/Sales Ratio
0.59x
TTM Avg
1.89x
3Y Avg
1.89x
5Y Avg
1.89x
Market Cap
$14.09M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$13.97M
EV/Sales Ratio
47.00x
TTM Avg
16.53x
3Y Avg
4.93x
5Y Avg
3.45x
Market Cap
$15.01M
EV/Sales Ratio
1.20x
TTM Avg
1.84x
3Y Avg
1.65x
5Y Avg
2.08x
Market Cap
$13.44M
EV/Sales Ratio
63.31x
TTM Avg
135.82x
3Y Avg
650.44x
5Y Avg
556.96x
Market Cap
$13.01M
EV/Sales Ratio
0.94x
TTM Avg
1.49x
3Y Avg
1.84x
5Y Avg
2.28x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Obsidian Therapeutics Inc. (OBX) | $14.29M | N/A | N/A | N/A | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $14.04M | 0.59x | 1.89x | 1.89x | 1.89x |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.09M | N/A | N/A | N/A | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $13.97M | 47.00x | 16.53x | 4.93x | 3.45x |
| IN8bio, Inc. (INAB)vs › | $13.71M | N/A | N/A | N/A | N/A |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $15.01M | 1.20x | 1.84x | 1.65x | 2.08x |
| Optimi Health Corp. (OPTH)vs › | $13.44M | 63.31x | 135.82x | 650.44x | 556.96x |
| Pasithea Therapeutics Corp. (KTTA)vs › | $15.15M | N/A | N/A | N/A | N/A |
| Cytosorbents Corporation (CTSO)vs › | $13.01M | 0.94x | 1.49x | 1.84x | 2.28x |
| Passage Bio, Inc. (PASG)vs › | $13.27M | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
